PhRMA Prescription Drug Abuse Position Paper

The Pharmaceutical Research and Manufacturers of America (PhRMA) and its members are committed to supporting the appropriate use of prescription medicines and working with others to address the diversion, misuse, and abuse of prescription medicines. When used appropriately and under the direction and care of a licensed health care professional, prescription medicines can improve and save lives.  However, prescription medicines can cause negative health consequences if they are used inappropriately and not as intended.  

 

Backgrounder: Impact of Restricted Drug Coverage

Restrictions on drug coverage can harm patients and increase health care costs.

View the Backgrounder

Improving Prescription Medicine Adherence is Key to Better Health Care

Successful treatment of disease with prescription medicinesrequires consistent use of the medicines as prescribed. Yet research shows that medicines commonly are not used asdirected. Nonadherence to medicines is a major healthcare cost and quality problem, with numerous studies showing high rates of nonadherence directly related to poor clinical outcomes, high health care costs, and lost productivity.

Rx Minute: Statins Value to Society & Risk Factors Linked to Alzheimer's

A recent article published in Health Affairs highlights the remarkable impact of cholesterol-lowering drugs known as statins on the treatment of cardiovascular disease in the U.S.

Nearly 400 Novel Medicines in Development for Infectious Diseases

America’s biopharmaceutical research companies are developing 394 new medicines for infectious diseases, according to a new report released today by the Pharmaceutical Research and Manufacturers of America (PhRMA). 

Alzheimer’s - The Puzzle, The Partners, The Path Forward

Alzheimer’s Disease (AD) is a debilitating neurodegenerative disease that currently afflicts more than 5 million people in the U.S. In an effort to catalyze progress in AD innovation and R&D, PhRMA, in partnership with the Alzheimer’s Association and the Alzheimer’s Drug Discovery Foundation, is hosting an all-day forum to convene top industry and academic scientists, patients, policymakers, and other stakeholders.

PhRMA 2013 Industry Profile

Medicines in Development for Vaccines 2013

America’s biopharmaceutical companies are currently developing 271 vaccines to prevent – and in some cases treat – a variety of conditions, including infectious diseases, various forms of cancer and neurological disorders, according to a new report released today by the Pharmaceutical Research and Manufacturers of America (PhRMA) 

Clinical Trials: Neurological Disorders

There are more than 2,000 clinical trials listed in the National Institutes of Health database – www.clinicaltrials.gov – for neurological disorders, such as Alzheimer’s disease, brain tumors, chronic pain, epilepsy, headache, multiple sclerosis and Parkinson’s disease.  Of those trials, more than 350 are either recruiting patients or have not yet started recruiting patients.  This information is potentially valuable to patients still seeking effective treatments for one of the many neurological disorders.  It provides a new therapeutic option to

Clinical Trials: Heart Disease and Stroke

There are more than 2,000 clinical trials listed in the National Institutes of Health database – www.clinicaltrials.gov – for heart disease and stroke.  Of those trials, more than 400 are either recruiting patients or have not yet started recruiting patients.  This information is potentially valuable to patients still seeking effective treatments for heart disease or stroke.  It provides a new therapeutic option to discuss with physicians.  For current information about the clinical trials that are recruiting or about to recruit patients, please c

Pages

Subscribe to RSS - Publications